Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

BACKGROUND Chronic obstructive pulmonary disease (COPD) results from a progressive decline in lung function, which is thought to be the consequence of airway inflammation. We hypothesized that antiinflammatory therapy with inhaled corticosteroids would slow this decline. METHODS We enrolled 1116 persons with COPD whose forced expiratory volume in one second (FEV1) was 30 to 90 percent of the predicted value in a 10-center, placebo-controlled, randomized trial of inhaled triamcinolone acetonide administered at a dose of 600 microg twice daily. The primary outcome measure was the rate of decline in FEV1 after the administration of a bronchodilator. The secondary outcome measures included respiratory symptoms, use of health care services, and airway reactivity. In a substudy of 412 participants, we measured bone density in the lumbar spine and femur at base line and one and three years after the beginning of treatment. RESULTS The mean duration of follow-up was 40 months. The rate of decline in the FEV1 after bronchodilator use was similar in the 559 participants in the triamcinolone group and the 557 participants in the placebo group (44.2+/-2.9 vs. 47.0+/-3.0 ml per year, P= 0.50). Members of the triamcinolone group had fewer respiratory symptoms during the course of the study (21.1 per 100 person-years vs. 28.2 per 100 person-years, P=0.005) and had fewer visits to a physician because of a respiratory illness (1.2 per 100 person-years vs. 2.1 per 100 person-years, P=0.03). Those taking triamcinolone also had lower airway reactivity in response to methacholine challenge at 9 months and 33 months (P=0.02 for both comparisons). After three years, the bone density of the lumbar spine and the femur was significantly lower in the triamcinolone group (P < or = 0.007). CONCLUSIONS Inhaled triamcinolone does not slow the rate of decline in lung function in people with COPD, but it improves airway reactivity and respiratory symptoms and decreases the use of health care services for respiratory problems. These benefits should be weighed against the potential long-term adverse effects of triamcinolone on bone mineral density.

[1]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[2]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[3]  H. Boushey.  Glucocorticoid therapy for chronic obstructive pulmonary disease. , 1999, The New England journal of medicine.

[4]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[5]  D. Postma,et al.  Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.

[6]  B. Beghé,et al.  Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease , 1998, Thorax.

[7]  R. Zuwallack,et al.  Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. , 1998, American journal of respiratory and critical care medicine.

[8]  J. Bourbeau,et al.  Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. , 1998, Thorax.

[9]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[10]  S. R. Rutgers,et al.  Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD. , 1998, American journal of respiratory and critical care medicine.

[11]  J. Brazier,et al.  Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. , 1997, Thorax.

[12]  R. Wise.  Changing smoking patterns and mortality from chronic obstructive pulmonary disease. , 1997, Preventive medicine.

[13]  D. Joyce,et al.  Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. , 1997, Chest.

[14]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[15]  K. Chapman,et al.  Prevalence of Inhaled Corticosteroid Use among Patients with Chronic Obstructive Pulmonary Disease: A Survey , 1997, The Annals of pharmacotherapy.

[16]  P. Sly,et al.  Allergic respiratory disease: strategic targets for primary prevention during childhood. , 1997, Thorax.

[17]  D. Postma,et al.  Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[18]  C. P. Schayck,et al.  Do patients with COPD benefit from treatment with inhaled corticosteroids? , 1996, The European respiratory journal.

[19]  D. Postma,et al.  Effects of long-term treatment with corticosteroids in COPD. , 1996, Chest.

[20]  L. Fabbri,et al.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. , 1996, Thorax.

[21]  D. Zamir,et al.  Inhaled budesonide therapy for patients with stable COPD. , 1995, Chest.

[22]  M. Cosio,et al.  Alveolar inflammation and its relation to emphysema in smokers. , 1995, American journal of respiratory and critical care medicine.

[23]  A. Buist,et al.  Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. , 1993, Chest.

[24]  C. van Weel,et al.  Slowing the Deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids: A 4-Year Prospective Study , 1993, Annals of Internal Medicine.

[25]  P. Burge,et al.  Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. , 1993, Thorax.

[26]  D. Postma,et al.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. , 1992, The New England journal of medicine.

[27]  D. Dockery,et al.  Longitudinal lung function decline in subjects with respiratory symptoms. , 1992, The American review of respiratory disease.

[28]  J. Paton,et al.  Measuring compliance with inhaled medication in asthma. , 1992, Archives of disease in childhood.

[29]  E. Bleecker,et al.  The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation , 1992 .

[30]  A. Buist,et al.  Spirometry in the Lung Health Study. 1. Methods and quality control. , 1991, The American review of respiratory disease.

[31]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[32]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.